Our findings identify the SMO-ATF2-IRP1-FPN/TFRC axis as a central regulator of cochlear iron homeostasis and propose SMO inhibition as a promising therapeutic strategy for SNHL through precise modulation of iron metabolism. The gene discussed is ATF2; the disease is sensorineural hearing loss disorder.